EU MDR & IVDR Packaging Compliance: Regulatory Guide
EU MDR & IVDR Packaging Compliance: Regulatory Guide
EU MDR and IVDR have fundamentally changed the regulatory requirements for medical device packaging — the burden of evidence is higher than under MDD and the notified body scrutiny of packaging documentation is significantly increased.
Packaging Requirements in EU MDR Annex I
EU MDR Annex I (General Safety and Performance Requirements — GSPR) establishes the fundamental packaging requirements that all CE-marked medical devices must meet. Key packaging-relevant GSPRs include:
GSPR 11: Devices Supplied Sterile
Section 11.1: Devices supplied in sterile condition must be manufactured, processed, and packaged in appropriate controlled conditions (cleanroom environment per applicable standards). The sterile barrier system must maintain sterility to the point of use throughout the intended shelf life and must be designed to allow aseptic presentation. Validation of the sterile barrier per ISO 11607-1/11607-2 is required evidence for conformity with GSPR 11.
GSPR 23: Label and Instructions for Use
Section 23.2 specifies the mandatory content of device labels. For sterile devices: name and description of device, content of the packaging (number of items), UDI carrier (as required by Article 27), expiry date, sterilisation method indicator (ISO 15223-1 symbols), manufacturer name and address, CE marking with notified body number, MDEL number (if applicable), and storage/handling instructions. Labels must remain legible throughout the device shelf life.
UDI Requirements for Medical Device Packaging
EU MDR Article 27 and the associated EU UDI database (EUDAMED) requirements make UDI labelling mandatory for all CE-marked medical devices. Key UDI packaging requirements:
| Device Class | UDI on Label Deadline | Carrier Format Required |
|---|---|---|
| Class III (implantables) | May 2021 (in force) | Linear barcode + 2D DataMatrix (GS1) |
| Class IIb | May 2023 (in force) | Linear barcode + 2D DataMatrix (GS1) |
| Class IIa and Class I (sterile/measuring) | May 2025 (in force) | 2D DataMatrix (GS1) required; linear optional |
| Class I (general) | May 2027 | 2D DataMatrix (GS1) required |
| Reusable devices (each use) | Per device class deadline | Direct part marking or durable label |
Technical File Documentation for Packaging
Under EU MDR, the technical file must include a complete package of packaging documentation. Notified bodies review packaging documentation as part of the conformity assessment for Class IIa and above. Required packaging documentation includes: packaging design specifications and drawings, material specifications and supplier Declarations of Conformity (food contact, biocompatibility), sterile barrier validation reports (IQ/OQ/PQ per ISO 11607-2), shelf life validation reports (accelerated and real-time aging per ISO 11607-1), distribution performance testing reports (ASTM D4169 or ISTA), and a summary of how the packaging design addresses applicable GSPRs. Incomplete packaging documentation is a common major finding in MDR conformity assessment reviews.
Post-Market Surveillance for Packaging
EU MDR Article 83 requires a proactive post-market surveillance (PMS) system that collects and analyses data from the market on device and packaging performance. Packaging-relevant PMS activities include: monitoring of field complaints related to packaging (damaged packaging, difficult-to-open, labelling errors), analysis of adverse event reports where packaging failure may be a contributing factor, trending of internal packaging non-conformances and customer complaints, and periodic review of packaging performance data in the Post-Market Surveillance Report (PMSR) or Periodic Safety Update Report (PSUR). PMS data feeds back into the risk management file (ISO 14971) and may trigger packaging design changes or revalidation.
Frequently Asked Questions
What packaging documentation does a notified body expect for a Class IIb device?
For a Class IIb medical device under EU MDR, a notified body conducting conformity assessment (Annex IX or X) will expect to see: sterile barrier validation reports covering all packaging configurations and sterilisation methods (ISO 11607-1/11607-2), shelf life validation data with supporting accelerated and real-time aging study reports, distribution simulation testing reports (ASTM D4169 or equivalent ISTA), labelling specifications and label samples confirmed against Annex I GSPR 23 requirements, UDI implementation documentation, biocompatibility assessment for any patient-contact packaging material (ISO 10993), and evidence that packaging design controls were conducted under the quality management system (ISO 13485 §7.3 compliance).
Does the packaging change control process need to comply with EU MDR?
Yes — under EU MDR, any change to a CE-marked device (including its packaging) must be assessed through a formal change control process documented within the ISO 13485 quality management system. Changes must be evaluated for their potential impact on the device's safety and performance and on GSPR conformity. Significant changes (those affecting sterile barrier performance, labelling, or material composition) must be reported to the notified body and may require re-assessment of the technical file or updated conformity assessment. The manufacturer's change control SOP must define the criteria for significant vs. non-significant packaging changes.
How does IVDR differ from MDR for packaging requirements?
The IVDR 2017/746 packaging requirements are structurally identical to MDR — the same Annex I GSPR structure applies, with the same GSPR 11 (sterile packaging), GSPR 20 (labelling), and UDI requirements. The primary differences relate to risk classification: IVDR Class D devices (highest risk, equivalent to Class III MDR) have been subject to the most rigorous notified body scrutiny. Self-tests (Class B) and near-patient testing products have specific labelling requirements under IVDR that differ from MDR. Manufacturers with both MDR and IVDR product ranges should use harmonised packaging documentation processes to maximise efficiency across both regulatory frameworks.